Management of HIV-hepatitis B co-infection

Marc Mendelson
Southern African Journal of HIV Medicine | Vol 12, No 1 | a209 | DOI: | © 2011 Marc Mendelson | This work is licensed under CC Attribution 4.0
Submitted: 15 December 2011 | Published: 19 April 2011

About the author(s)

Marc Mendelson, Desmond Tutu HIV Foundation

Full Text:

PDF (296KB)


HIV-hepatitis B virus (HBV) co-infected patients are at risk of increased morbidity and mortality. Early recognition of dual infection is a critical factor in directing appropriate therapy, and HBV screening should therefore be undertaken at the time of HIV diagnosis. Vaccination against HBV should be considered for all HIV patients who are not yet infected with HBV. Antiretroviral therapy containing two antiretrovirals active against HBV should be started if the patient either has symptomatic liver disease or is asymptomatic with a CD4 count of <350 cells/µl.


No related keywords in the metadata.


Total abstract views: 2350
Total article views: 1884

Crossref Citations

No related citations found.